Skip to main navigation Skip to search Skip to main content

C19: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19

Project: Research

Project Details

StatusFinished
Effective start/end date07/1/20 → 06/30/22

Funding

  • Regeneron Pharmaceuticals Incorporated: $53,664.82